Literature DB >> 24055079

Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.

Guanghui Deng1, Baowei Zhao, Yingli Ma, Qiongfeng Xu, Hailong Wang, Liuqing Yang, Qing Zhang, Taylor B Guo, Wei Zhang, Yang Jiao, Xin Cai, Jinqiang Zhang, Houfu Liu, Xiaoming Guan, Hongtao Lu, Jianing Xiang, John D Elliott, Xichen Lin, Feng Ren.   

Abstract

We have discovered a novel complex crystal structure of the PHD2 enzyme with its inhibitor, the 2,8-diazaspiro[4.5]decan-1-one analogue 4b. The widely reported salt bridge between Arg383 of the enzyme and its inhibitors in all complex structures published thus far was not observed in our case. In our complex structure compound 4b forms several novel interactions with the enzyme, which include a hydrogen bond with Arg322, a π-cation interaction with Arg322, a π-π stacking with Trp389, and a π-π stacking with His313. Guided by the structural information, SAR studies were performed on the 2,8-diazaspiro[4.5]decan-1-one series leading to the discovery of compound 9p with high potency and good oral pharmacokinetic profile in mice.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2,8-Diazaspiro[4.5]decan-1-one; Hypoxia inducible factor (HIF); PHD inhibitors; PHD2 crystal structure; Prolyl hydroxylase domain-containing protein 2 (PHD2); SAR study

Mesh:

Substances:

Year:  2013        PMID: 24055079     DOI: 10.1016/j.bmc.2013.08.046

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors.

Authors:  Irina N Gaisina; Sue H Lee; Navneet A Kaidery; Manel Ben Aissa; Manuj Ahuja; Natalya N Smirnova; Sushama Wakade; Arsen Gaisin; Megan W Bourassa; Rajiv R Ratan; Sergey V Nikulin; Andrey A Poloznikov; Bobby Thomas; Gregory R J Thatcher; Irina G Gazaryan
Journal:  ACS Chem Neurosci       Date:  2018-01-17       Impact factor: 4.418

2.  Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials.

Authors:  Tzu-Lan Yeh; Thomas M Leissing; Martine I Abboud; Cyrille C Thinnes; Onur Atasoylu; James P Holt-Martyn; Dong Zhang; Anthony Tumber; Kerstin Lippl; Christopher T Lohans; Ivanhoe K H Leung; Helen Morcrette; Ian J Clifton; Timothy D W Claridge; Akane Kawamura; Emily Flashman; Xin Lu; Peter J Ratcliffe; Rasheduzzaman Chowdhury; Christopher W Pugh; Christopher J Schofield
Journal:  Chem Sci       Date:  2017-09-11       Impact factor: 9.825

3.  Use of cyclic peptides to induce crystallization: case study with prolyl hydroxylase domain 2.

Authors:  Rasheduzzaman Chowdhury; Martine I Abboud; Tom E McAllister; Biswadip Banerji; Bhaskar Bhushan; John L Sorensen; Akane Kawamura; Christopher J Schofield
Journal:  Sci Rep       Date:  2020-12-15       Impact factor: 4.379

Review 4.  Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors.

Authors:  James P Holt-Martyn; Anthony Tumber; Mohammed Z Rahman; Kerstin Lippl; William Figg; Michael A McDonough; Rasheduzzaman Chowdhury; Christopher J Schofield
Journal:  Medchemcomm       Date:  2019-03-01       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.